Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response
Presenter: Ines Pires da Silva
Session: Poster session 08
134P - Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)
Presenter: Arutha Kulasinghe
Session: Poster session 08
135P - Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
Presenter: Adrien Costantini
Session: Poster session 08
136P - Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study
Presenter: Benoit You
Session: Poster session 08
137P - Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker
Presenter: Sebastien Salas
Session: Poster session 08
138P - Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics
Presenter: Amelie Franken
Session: Poster session 08
139P - Multimodal prognosis modeling of advanced NSCLC treated with first-line immunochemotherapy: Integrating genomic and microenvironmental data
Presenter: Yi Hu
Session: Poster session 08
140P - Mining metastatic lymph nodes for response to immune checkpoint therapy in non-small cell lung cancer
Presenter: Elena Donders
Session: Poster session 08
141P - Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study
Presenter: Benedetta Conte
Session: Poster session 08
142P - Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy
Presenter: Mai Hoshino
Session: Poster session 08